Levofloxacin Prophylaxis in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Davide Leardini1, Giacomo Gambuti1, Edoardo Muratore1

  • 1Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

PubMed

Insights

Levofloxacin prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HCT) did not reduce infections but increased quinolone-resistant strains. Gut microbiota was altered, with lower beneficial bacteria abundance in patients receiving prophylaxis.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Microbiology

Background:

  • The use of quinolones for infection prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HCT) is debated, with limited evidence, especially in pediatric patients.
  • This study addresses the controversy by evaluating levofloxacin prophylaxis in allo-HCT recipients.

Purpose of the Study:

  • To compare outcomes between patients receiving and not receiving levofloxacin (LVX) prophylaxis after allo-HCT.
  • To assess the impact of LVX prophylaxis on survival, graft-versus-host disease (GvHD), bloodstream infections, and gut microbiota composition.

Main Methods:

  • A single-center retrospective study analyzed 144 allo-HCT procedures in 143 patients.
  • Outcomes including overall survival, event-free survival, acute GvHD (aGvHD), and bloodstream infections were compared between patients receiving (n=74) or not receiving (n=70) LVX prophylaxis.
  • Gut microbiota composition was analyzed using 16S rRNA sequencing in a subgroup of 50 patients.

Main Results:

  • No significant differences were observed in key allo-HCT outcomes such as cumulative incidence of aGvHD, grade III-IV aGvHD, gut aGvHD, or bloodstream infections between the two groups.
  • Patients receiving LVX prophylaxis exhibited a higher incidence of quinolone-resistant bacterial strains (P = .001).
  • In the subgroup analysis, LVX prophylaxis was associated with a lower abundance of Blautia (P = .015), Enterococcus (P = .011), and Actinomyces (P = .07) at neutrophil engraftment.

Conclusions:

  • Levofloxacin prophylaxis in the context of allo-HCT does not appear to prevent infectious complications.
  • Prophylactic levofloxacin use is associated with an increased prevalence of antibiotic-resistant bacterial strains.
  • LVX prophylaxis significantly alters gut microbiota composition, reducing the abundance of certain beneficial bacteria.
Abstract